PDCD1 and esophageal squamous cell carcinoma: Third, our study only reported a short-term survival outcome, longer follow-up is necessary to evaluate the long-term clinical benefits of neoadjuvant PD-1 inhibitor combined with chemotherapy for locally advanced ESCC.